Geron to Announce Third Quarter Financial Results on November 5, 2020
Geron Corporation (Nasdaq: GERN) will release its third quarter 2020 financial results on November 5, 2020, after market close. The results will be discussed in a conference call at 4:30 p.m. ET the same day. The press release will be available on the company’s website. A live webcast of the call will also be accessible, with archived options available for 30 days. Geron is focused on developing its telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies.
- Geron focuses on a unique, first-in-class telomerase inhibitor, imetelstat, targeting hematologic myeloid malignancies.
- None.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.
A live, listen-only webcast will be available on the Company’s website at www.geron.com/investors/events. If you are unable to listen to the live call, an archived webcast will be available on the Company’s website for 30 days.
Participants may access the conference call live via telephone by pre-registering online using the following link, http://www.directeventreg.com/registration/event/7879966. Upon registration, a phone number, Direct Event Passcode and unique Registrant ID will be sent via email. This information will be needed in order to enter the conference call. Participants are advised to pre-register at least 10 minutes prior to joining the call.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
